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Colony stimulating factor‑1 receptor 
as a treatment for cognitive deficits 
postfractionated whole‑brain 
irradiation
Susanna Rosi
Abstract:
Whole‑brain irradiation (WBI) is commonly used to treat primary tumors of the central nervous systems 
tumors as well as brain metastases. While this technique has increased survival among brain tumor 
patients, the side effects of including a decline in cognitive abilities that are generally progressive. In 
an effort to combat WBI side effects, researchers explored the treatment of colony stimulating factor‑1 
receptor (CSF‑1R) inhibitor. Data show that when a CSF‑1R inhibitor is administered with fractionated 
WBI treatment, there is a decline in the number of resident and peripheral mononuclear phagocytes, 
a decrease in dendritic spine loss and a reduction in functional and memory deficits. CSFR‑1R 
inhibitors have displayed promising results as an effective counter‑treatment for WBI‑induced deficits. 
Further research is required to optimize treatment strategies, establish a treatment timeline and gain 
a better understanding of the long‑term side effects of targeting CSF‑1R as a treatment strategy for 
WBI symptoms. This paper is a review article. Referred literature in this paper has been listed in the 
references section. The datasets supporting the conclusions of this article are available online by 
searching various databases, including PubMed. Some original points in this article come from the 
laboratory practice in our research center and the authors’ experiences.
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Introduction
Primary tumors of the central nervous system (CNS) and brain metastases 
may be treated with whole-brain irradiation 
(WBI) (often delivered in 25–30 fractions 
for a total dosage of 55–60 Gy). The novel, 
enhanced treatments have resulted in 
lowered mortality rates but increased risks 
of detrimental side effects. In particular, 
progressive symptoms related to cognitive 
function present in approximately 50%–90% 
of long-term survivors (>6 months) after 
WBI treatment.[1] There is little treatment 
available for patients suffering from these 
cognitive abnormalities, as the cause of them 
is currently unknown. One dose of 10 Gy 
WBI causes periphery monocytes to gather 
in the CNS after 7 days of the single dosage.[2] 
Similarly, research shows that WBI initiates 
the actions of immune cells expressing 
MHCII, CD11c, and CD3.[3] Even though 
one study[4] did not see monocyte-derived 
macrophages in the WBI treated adult 
brain, this may be because of varying 
sources of radiation or discrepancies in 
monocyte quantification. This study shows 
that in combination with a certain colony 
stimulating factor-1 receptor (CSF-1R), 
fractionated WBI treatment (fWBI) improves 
functional outcomes by decreasing the 
amount of resident and peripherally-derived 
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mononuclear phagocytes and inhibiting the development 
of memory problems and dendritic spine loss (in mice).[5]
Modulating Whole‑brain 
Irradiation‑induced Cognitive Deficits: 
microglia or Monocytes?
CSF-1 signaling plays a major role in the development 
and function of mononuclear phagocytes.[6] Because 
of its receptor, CSF-1R, is expressed on the surface 
of CNS microglia and periphery monocytes, CSF-1R 
inhibition affects both cell types. Certain dosages of 
CSF-1R inhibitors can decrease the amount of microglia 
in mice. There is a 30%–50% reduction in microglia 
with a 300 ppm dose of PLX5622, a CSF-1R inhibitor,[5,7] 
and a nearly complete elimination (>95%) of microglia 
with either a 1,200 dose of PLX5622 or a 290 ppm dose 
of PLX3397 (an inhibitor similar to PLX5622).[8] Both 
levels of microglial depletion block WBI-induced 
dendritic spine loss and prevent the development of 
cognitive disabilities.[5,9] Dendritic spine loss becomes 
apparent between 2 weeks and a month (the point 
where cognition is measured) following fWBI and 
continues until several months posttreatment.[5,10] 
Despite knowing that radiation stimulates microglia 
and peripherally derived monocytes,[2,11] it is unclear 
why WBI and fWBI cause dendritic spine loss. WBI 
increases the brain’s concentration of chemoattractant 
cytokine CCL2, a molecule that stimulates CNS uptake 
of peripherally derived CCR2+ monocytes.[12] CCR2 
is a chemokine receptor absent from brain microglia[2] 
and the stimulation of CCR2-CCL2 signaling causes 
the accumulation of CCR2-expressing monocytes (also 
known as “inflammatory monocytes”) in the injured 
tissue. These CCR2-expressing monocytes then 
transform into macrophages with proinflammatory 
properties.[13] Conversely, a lack of CCR2 molecules 
impedes the movement of CCR2+ Ly6Chigh from 
the bone marrow to the blood stream[14] and reduces 
the WBI-induced neural and cognitive deficits.[11] 
Ly6Chigh monocyte concentrations are reduced in the 
blood by PLX5622 treatment and in the CNS by CSF-1R 
antagonism, whereas Ly6Clow concentration is not 
affected.[5] In the peripheral nervous system (PNS), 
Ly6Chigh differentiate into macrophages or dendritic 
cells within damaged tissues. It is postulated that in 
neuroinflammatory models (such as those for traumatic 
brain injury and multiple sclerosis), Ly6Chigh monocytes 
regulate inflammatory responses of the CNS and that 
microglia aid in tissue restoration.[14] Stimulation of these 
monocytes and microglia possibly enhances neuronal 
damage post‑WBI, but the degree of influence these cells 
have on neuroinflammation following WBI and fWBI 
is currently unclear. Additional studies are warranted 
to examine the specific cell phenotypes mediating the 
learning and memory performance.
Colony Stimulating Factor‑1 Receptor 
Inhibition as Potential Therapy to Prevent 
Whole‑brain Irradiation‑induced Cognitive 
Deficits
While CSF-1R inhibition remains one of the principal 
ways to treat and prevent cognitive deficits post‑WBI 
treatment, more studies are needed to elucidate the 
treatment’s safety, effectiveness, and mechanism of 
action. First, the function of CSF-1R signaling differs 
depending on age. Because CSF-1R is naturally 
expressed in cortical neurons, immature neurons, neural 
progenitor cells, and following chemical injury, CSF-1R 
treatment under these conditions may have a direct 
effect on neural function.[6] Second, CSF-1R treatment 
may produce different effects regarding inflammation 
in the CNS, as well as in the PNS due to monocytes 
expressing both CSF-1R and CCR2 and microglia 
expressing only CSF-1R. CSFR-1 inhibition most likely 
decreases microglia concentration, but its effects on 
monocytes and peripheral immune responses is widely 
unknown. PLX5622 treatment caused a nearly 30% 
reduction in Ly6Chigh monocytes but scarcely affected 
Ly6Clowmonocytes in humans. Other results display 
a decrease in nonclassical CD14+ CD16+ monocytes but 
not the classical CD14+ CD16− monocytes following 
treatment with the CSF-1R antibody.[15] Small inhibitors 
opposing the antibody, specificity of the inhibitor and 
antibody, or varied reactions to CSF-1R inhibition 
in rodents and humans may cause the discrepancies 
between the classical and nonclassical monocytes. In 
addition, little is known about the relationships between 
CSF-1/CSF-1R and CCL2/CCR2 signaling pathways. 
Third, cognitive deficits generally appear months to 
years following WBI treatment. While it is unknown 
if CSF-1R inhibition during irradiation can prevent 
chronic cognitive abnormalities, several animal studies 
displayed CSF-1R inhibition to last between 7 days and 
12 weeks. Since macrophages’ roles differ depending 
on their microenvironments, infiltrating monocytes and 
macrophages may change their function from small scale 
repair to long-term restoration. More studies need to 
examine the therapeutic window and long-term effects 
of CSF-1R treatment. Finally, even though WBI treatment 
is primarily used on brain tumor patients, the majority 
of studies focus on normal brains due to the additional 
treatments brain tumor patients often require. CSF-1R 
inhibitors may interfere with other treatments and 
the tumor microenvironment of brain-tumor patients, 
as CSF-1R inhibition primarily affects tumor related 
macrophages. Even though over 50% of tumors recur 
after CSF-1R treatment,[16] the inhibitor also appears 
to prevent glioma development and interact with the 
tumor’s macrophages.[17] More preclinical studies need 
to be conducted in brain tumor models to examine 
cognition following CSF-1R inhibitor treatment.
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